TSE:VPH Valeo Pharma (VPH) Stock Price, News & Analysis C$0.10 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's RangeC$0.10▼C$0.1050-Day RangeC$0.08▼C$0.1652-Week RangeC$0.06▼C$0.39Volume10,000 shsAverage Volume61,392 shsMarket CapitalizationC$9.87 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsHeadlinesStock AnalysisChartCompetitorsEarningsHeadlines Get Valeo Pharma alerts: Email Address Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Valeo Pharma Stock (TSE:VPH)Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson's disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. It also offers Hesperco, a flavonoid formulation used for immune support; Ethacrynate Sodium; and Amikacin, an antibiotic. In addition, the company provides Ametop Gel 4% for skin anesthesia prior to injection or cannulation; Sabizabulin, an antiviral and anti-inflammatory agent for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and death; Simbrinza, ophthalmic drops to treat openangle glaucoma or ocular hypertension; Xiidra, a prescription based eye-drop to treat dry eye disease; and Allerject, a portable voice-activated epinephrine injector for emergency treatment of serious allergic reactions. Its primary therapeutic areas include respiratory/allergy, ophthalmology, neurology, oncology, and specialty products. The company was incorporated in 2003 and is based in Kirkland, Canada.Read More VPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VPH Stock News HeadlinesJuly 20, 2024 | theglobeandmail.comClosing Bell: Valeo Pharma Inc 12.0 Pct Debs down on Monday (VPH-DB)May 5, 2024 | finance.yahoo.comBullish Valeo Pharma Insiders Loaded Up On CA$1.20m Of StockJuly 26, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."April 9, 2024 | finance.yahoo.comVALEO PHARMA TO PRESENT AT THE 2024 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCEApril 1, 2024 | theglobeandmail.comValeo Pharma: Top 25 Undervalued Toronto Stock Exchange Stocks (VPH)March 22, 2024 | finance.yahoo.comVALEO PHARMA ANNOUNCES APPOINTMENT OF MR. AL MOGHADDAM TO BOARD OF DIRECTORSMarch 16, 2024 | markets.businessinsider.comValeo Pharma’s Strategic Moves Signal Potential for EBITDA Positivity and Stock CatalystsMarch 14, 2024 | finance.yahoo.comVALEO PHARMA REPORTS FIRST QUARTER 2024 RESULTSJuly 26, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."March 7, 2024 | finance.yahoo.comVALEO PHARMA TO HOST FIRST QUARTER 2024 RESULTS CONFERENCE CALL / WEBCASTFebruary 14, 2024 | uk.finance.yahoo.comNews Flash: 2 Analysts Think Valeo Pharma Inc. (TSE:VPH) Earnings Are Under ThreatFebruary 13, 2024 | finance.yahoo.comVALEO PHARMA ANNOUNCES BOARD OF DIRECTORS CHANGESFebruary 3, 2024 | msn.comBiden to release proposed U.S. budget plan on March 11February 2, 2024 | finance.yahoo.comVALEO PHARMA AMENDS AGREEMENT WITH NOVARTIS PHARMACEUTICALS CANADA FOR (Pr)XIIDRA® IN CANADA AND CREDIT FACILITY WITH SAGARD HEALTHCARE ROYALTY PARTNERS, LPJanuary 29, 2024 | finance.yahoo.comVALEO PHARMA REPORTS RECORD ANNUAL REVENUES FOR FISCAL YEAR 2023January 22, 2024 | finance.yahoo.comVALEO PHARMA TO HOST FOURTH QUARTER AND YEAR-END 2023 RESULTS CONFERENCE CALL / WEBCASTDecember 16, 2023 | morningstar.comValeo Pharma Inc Ordinary Shares VPHDecember 11, 2023 | theglobeandmail.comClosing Bell: Valeo Pharma Inc 12.0 Pct Debs flat on Wednesday (VPH-DB)See More Headlines Receive VPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Valeo Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings6/13/2024Today7/26/2024Next Earnings (Estimated)9/11/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:VPH CUSIPN/A CIKN/A Webwww.valeopharma.com Phone514-694-0150FaxN/AEmployees100Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-28,430,000.00 Net Margins-52.37% Pretax MarginN/A Return on EquityN/A Return on Assets-23.07% Debt Debt-to-Equity RatioN/A Current Ratio0.49 Quick RatioN/A Sales & Book Value Annual SalesC$54.29 million Price / Sales0.18 Cash FlowN/A Price / Cash FlowN/A Book ValueC($0.48) per share Price / Book-0.21Miscellaneous Outstanding Shares98,660,000Free FloatN/AMarket CapC$9.87 million OptionableNot Optionable Beta2.59 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Steven Saviuk CA (Age 65)Vice Chairman, President & CEO Comp: $250kMr. Kyle SteigerSenior VP & Chief Commercial OfficerMr. Pascal TougasChief Financial OfficerMr. Frederic DumaisDirector of Communications & Investor RelationsMr. Guy-Paul AllardVP of Legal Affairs & Corporate SecretaryMr. Jean Francois FournierHead of Ophthalmology Business UnitMore ExecutivesKey CompetitorsViridium Pacific GroupCVE:VIRCharlotte's WebTSE:CWEBZomedica Pharmaceuticals Corp. (ZOM.V)CVE:ZOMInMed PharmaceuticalsTSE:INMeta GrowthCVE:METAView All Competitors VPH Stock Analysis - Frequently Asked Questions How have VPH shares performed this year? Valeo Pharma's stock was trading at C$0.18 at the beginning of the year. Since then, VPH stock has decreased by 44.4% and is now trading at C$0.10. View the best growth stocks for 2024 here. How were Valeo Pharma's earnings last quarter? Valeo Pharma Inc. (TSE:VPH) released its earnings results on Thursday, June, 13th. The company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by $0.03. The company had revenue of $14.13 million for the quarter, compared to analysts' expectations of $15.50 million. How do I buy shares of Valeo Pharma? Shares of VPH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:VPH) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Valeo Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Valeo Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.